NCT07639957 The Role of Gender in Borderline Personality Disorder
| NCT ID | NCT07639957 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Heidelberg |
| Condition | Borderline Personality Disorder (BPD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-05-29 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2026-05-29 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a mixed-methods, single-arm cross-sectional study comprising 1) a qualitative, exploratory, critical-constructivist content analysis examining the significance of gender in relationship experiences and self-perception among individuals with borderline personality disorder and various gender identities, and 2) a pilot study on the use of the Single-Category Implicit Association Test (SC-IATs, adapted from von Hippel et al., 2018) as preparation for a larger-scale experimental psychological study using the SC-IAT to assess implicit gender- and BPD-related thought processes in people with borderline personality disorder and various gender identities. 15 individuals with BPD and different gender identities will be assessed. The research questions are: 1. What gender-related relationship- and self-experiences can be identified in people with BPD? How do experiences relate to observer-coded and self-reported mentalization ability, as well as self-reported symptoms, experiences of stigmatization, and quality of life? 2. Is there preliminary evidence that Single-Category Implicit Association Tests (SC-IATs) are suitable and reliable instruments for measuring implicit gender- and BPD-related thought processes in people with BPD?
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent form 2. Individuals of all genders (target: n=5 with female gender identity, n=5 with nonbinary/trans\*/gender-non-conforming (TGNC) gender identity, n=5 with male gender identity) between the ages of 18 and 65 at the time of consent 3. Individuals with a BPD diagnosis made within the last 2 years (ICD-10: F60.3; DSM-5: 301.83, ICD-11: Borderline qualifier) 4. Understanding of the study procedure, ability and willingness to participate 5. The participant is able to read and understand the informed consent form and can provide a written, personally signed, and dated informed consent form. Exclusion Criteria: 1. Acute suicidal ideation or acute psychotic symptoms reported by the patient or suspected 2. Insufficient language skills (i.e., knowledge of German or English)
Contact & Investigator
Sophie Hauschild, Dr.
PRINCIPAL INVESTIGATOR
Institute for Psychosocial Prevention and Psychotherapy, University Hospital Heidelberg
Frequently Asked Questions
Who can join the NCT07639957 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Borderline Personality Disorder (BPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07639957 currently recruiting?
Yes, NCT07639957 is actively recruiting participants. Contact the research team at sophie.hauschild@med.uni-heidelberg.de for enrollment information.
Where is the NCT07639957 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT07639957 clinical trial?
NCT07639957 is sponsored by University Hospital Heidelberg. The principal investigator is Sophie Hauschild, Dr. at Institute for Psychosocial Prevention and Psychotherapy, University Hospital Heidelberg. The trial plans to enroll 15 participants.